Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

First SYGNIS QualiPhi®-based Products Launched by QIAGEN

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
QualiPhi®, now renamed SensiPhi®, targets sophisticated applications for DNA amplification.

SYGNIS AG has announced that its partner QIAGEN has launched the first two products of a series of kits based on SYGNIS’ proprietary amplification technology QualiPhi® now renamed SensiPhi®.

The two kits, REPLI-g WTA Single Cell Kit and REPLI-g Cell WGA & WTA Kit, are available now and will be commercialized globally through QIAGEN’s established distribution channels. The product launches result from a global exclusive license agreement with QIAGEN signed in 2012.

“We are at the beginning of a series of product launches that we believe will establish our polymerase as the potential future gold standard for isothermal amplification of DNA”, Pilar de la Huerta, CEO of SYGNIS stated.

Huerta continued, “With the launch of the first products based on our proprietary technology, SYGNIS continues to deliver on its objectives. It is a mark of our success as a company to have our product commercialized by the world leader QIAGEN.”

“We are very pleased with the launch of our new kits based on the polymerase provided by SYGNIS”, commented Achim Ribbe, Vice President Corporate Business Development Licensing at QIAGEN. “The REPLI-g WTA Single Cell and REPLI-g Cell WGA & WTA address key user challenges in NGS and other downstream applications, where DNA sequence analysis is limited by small amounts down to single cells of available sample material. To drive adoption of NGS in the clinical space, QIAGEN is building a broad portfolio of universal products including the REPLI-g Single Cell Kits which are compatible with any major NGS platform and which also support our own integrated sample-to-insight GeneReader workflow currently in development.”

SensiPhi® is the second generation of a DNA polymerase that was licensed from the Spanish National Research Council (CSIC) in 2010. Due to its unique properties, first studies suggest that it has the potential to improve the amplifications of whole genomes and large stretches of DNA.

SYGNIS’ SensiPhi® is a high efficiency, high fidelity polymerase for DNA amplification which conveys the outstanding properties in terms of speed, accuracy and length of DNA fragments to be amplified.

It differs from PCR since it provides generic amplification of the complete genome, whereas PCR is designed to detect predefined target sequences, and therefore only amplifies specific, mostly very short fragments of the DNA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS, ECACC Collaborate
Collaboration aims to expand SYGNIS’ Caco-2 business in Europe.
Friday, September 23, 2016
SYGNIS AG Signs Distribution Agreement with LABGENE Scientific
Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing and single cell analysis applications.
Friday, September 18, 2015
SYGNIS AG Signs Non-Exclusive Distribution Agreement with GeneWorks Pty Ltd
Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing and single cell analysis applications.
Tuesday, August 25, 2015
SYGNIS AG Signs Distribution Agreement with Chinese Nanodigmbio Co. Ltd.
Distribution agreement covers the entire SYGNIS portfolio of powerful tools addressing key challenges in NGS and single cell analysis.
Saturday, August 22, 2015
SYGNIS Signs Initial Distribution Agreement with FUNAKOSHI
TruePrime™ family for whole genome amplification without the need of synthetic random primers on stock and ready for distribution in Japan.
Thursday, March 05, 2015
SYGNIS Signs Initial Non-Exclusive Distribution Agreement with BioCat
TruePrime™ Single Cell WGA kit to be launched early 2015.
Tuesday, December 30, 2014
SYGNIS Announces Double Switch Technology Patent Deal with SYSTASY
Company reiterates strategic deals with leading industry partners.
Tuesday, May 13, 2014
SYGNIS Reports Financial Results for a Successful Fiscal Year 2013
First products launched based on QualiPhi® now renamed SensiPhi® in early 2014.
Wednesday, April 02, 2014
SYGNIS AG Successfully Completes Rights Offering and Private Placement
Company plans to use EUR 2.7 million to finance its operating business and further growth.
Monday, October 28, 2013
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Ribosome Recycling as a Drug Target
Researchers explain mechanism that recycles bacterial ribosomes stalled on messenger RNAs that lack termination codons.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!